TetraKit Technologies and TRIMT have successfully completed the initial preclinical development of 18F-Flutrahexin, a fluorine-18 labeled analog of 68Ga-Trivehexin. It’s currently considered the best-in-class PET tracer for imaging αvβ6-integrin, a tumor marker highly expressed in several aggressive cancers. Early synthesis and in vivo studies of 18F-Flutrahexin indicate strong potential for advanced PET diagnostics in cancers such as pancreatic ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal and ovarian cancers, and parathyroid adenoma.

This milestone is the result of a collaboration between TetraKit Technologies, a pioneer in theranostic radiolabeling through its TetraKit Platform, and TRIMT, a leading developer of αvβ6-integrin-targeting radiopharmaceuticals. The project not only advances a next-generation diagnostic agent but also lays the foundation for therapeutic applications using radiohalogens like ¹³¹I, ¹²³I, and ²¹¹At, all enabled via the versatile TetraKit Platform.

TetraKit and TRIMT are now actively seeking partners to accelerate the clinical translation of 18F-Flutrahexin and expand the reach of TetraKit’s platform technology to new targets in nuclear and precision medicine. This collaboration represents a unique opportunity to shape the future of radiotheranostics.